PH-797804 is a novel N-phenylpyridinone inhibitor of p38 mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer and is also known to exerts anti-inflammatory properties.
ChEBI: A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.
ph-797804 is a novel, potent, atp-competitive and reversible inhibitor of human p38 map kinase. it specifically inhibits p38α with ic50 value of 26 nm and k(i) value of 5.8 nm.ph-797804 inhibits lps induced tnf-α and il-1β production in monocytes with a concentration-dependently manner. ph-797804 blocks rankl and m-csf induced osteoclast formation in primary rat bone marrow cells.orally administered ph-797804 suppresses tnf-α level in a dose-dependent manner in lps induced lewis rats and also in cynomolgus monkeys. additionally, ph-797804 has been shown to inhibit chronic inflammation in arthritis models induced by mouse collagen-induced or rat streptococcal cell wall (scw) extract.
PH-797804 is an orally active, potent and readily reversible ATP competitive inhibitor of the alpha isoform of human p38 MAP kinase. PH-797804 blocks inflammation-induced production of cytokines and proinflammatory mediators.
[1] hope hr1, anderson gd, burnette bl, compton rp, devraj rv, hirsch jl, keith rh, li x, mbalaviele g, messing dm, saabye mj,schindler jf, selness sr, stillwell li, webb eg, zhang j, monahan jb. anti-inflammatory properties of a novel n-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. j pharmacol exp ther. 2009 dec;331(3):882-95.
